Surfactant-enhanced DNA accessibility to nuclease accelerates phenotypic β-lactam antibiotic susceptibility testing of Neisseria gonorrhoeae
Abstract
Rapid antibiotic susceptibility testing (AST) for Neisseria gonorrhoeae (Ng) is critically needed to counter widespread antibiotic resistance. Detection of nucleic acids in genotypic AST can be rapid, but it has not been successful for β-lactams (the largest antibiotic class used to treat Ng). Rapid phenotypic AST for Ng is challenged by the pathogen's slow doubling time and the lack of methods to quickly quantify the pathogen's response to β-lactams. Here, we asked two questions: (1) Is it possible to use nucleic acid quantification to measure the β-lactam susceptibility phenotype of Ng very rapidly, using antibiotic-exposure times much shorter than the 1- to 2-h doubling time of Ng? (2) Would such short-term antibiotic exposures predict the antibiotic resistance profile of Ng measured by plate growth assays over multiple days? To answer these questions, we devised an innovative approach for performing a rapid phenotypic AST that measures DNA accessibility to exogenous nucleases after exposure to β-lactams (termed nuclease-accessibility AST [nuc-aAST]). We showed that DNA in antibiotic-susceptible cells has increased accessibility upon exposure to β-lactams and that a judiciously chosen surfactant permeabilized the outer membrane and enhanced this effect. We tested penicillin, cefixime, and ceftriaxone and found good agreement between the results of the nuc-aAST after 15–30 min of antibiotic exposure and the results of the gold-standard culture-based AST measured over days. These results provide a new pathway toward developing a critically needed phenotypic AST for Ng and additional global-health threats.
Additional Information
© 2020 Savela et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Received: June 29, 2019; Accepted: February 14, 2020; Published: March 19, 2020. We thank Adam Sukhija-Cohen, Sherrelle Banks, Matt Santos, and Yancy Granados at the AIDS Healthcare Foundation for their technical assistance with the clinical study and patient enrollment. We thank Peera Hemarajata at the UCLA Clinical Microbiology Laboratory for providing isolates and for discussion of gold-standard practices. We also thank Natasha Shelby for help with writing and editing this manuscript. Data Availability Statement: The authors declare that all the data supporting these findings are available within the article and its supplemental files. This work was funded in part by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) and the Wellcome Trust under the CARB-X program (federal award number IDSEP160030-02); the content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of HHS Office of the ASPR. This CARB-X project is a collaboration between Talis Biomedical Corp. and Caltech. This work was also supported by a Burroughs Wellcome Fund Innovation in Regulatory Science Award (1014981), an NIH National Research Service Award (NRSA) [5T32GM07616NSF] (to NGS), a grant from the Joseph J. Jacobs Institute for Molecular Engineering for Medicine, and a fellowship (to ESS) from Joan and Jerry Doren. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: The technology described in this publication is the subject of a patent application filed by Caltech. RFI has a financial interest in Talis Biomedical Corp. Caltech is a sub-awardee to Talis Biomedical Corp. on the CARB-X grant that partially funded this work. We thank Adam Sukhija-Cohen, Sherrelle Banks, Matt Santos, and Yancy Granados at the AIDS Healthcare Foundation for their technical assistance with the clinical study and patient enrollment. We thank Peera Hemarajata at the UCLA Clinical Microbiology Laboratory for providing isolates and for discussion of gold-standard practices. We also thank Natasha Shelby for help with writing and editing this manuscript. Author Contributions: Conceptualization: Emily S. Savela, Nathan G. Schoepp, Rustem F. Ismagilov. Data curation: Emily S. Savela, Nathan G. Schoepp, Justin C. Rolando. Formal analysis: Emily S. Savela, Nathan G. Schoepp, Matthew M. Cooper, Justin C. Rolando. Funding acquisition: Nathan G. Schoepp, Rustem F. Ismagilov. Investigation: Emily S. Savela, Nathan G. Schoepp, Matthew M. Cooper. Methodology: Emily S. Savela, Nathan G. Schoepp. Project administration: Rustem F. Ismagilov. Resources: Jeffrey D. Klausner, Olusegun O. Soge, Rustem F. Ismagilov. Supervision: Rustem F. Ismagilov Validation: Emily S. Savela, Nathan G. Schoepp, Matthew M. Cooper. Visualization: Emily S. Savela, Nathan G. Schoepp. Writing – original draft: Emily S. Savela, Nathan G. Schoepp. Writing – review & editing: Emily S. Savela, Nathan G. Schoepp, Matthew M. Cooper, Jeffrey D. Klausner, Olusegun O. Soge, Rustem F. Ismagilov.Attached Files
Published - journal.pbio.3000651.pdf
Supplemental Material - journal.pbio.3000651.s001.tif
Supplemental Material - journal.pbio.3000651.s002.tif
Supplemental Material - journal.pbio.3000651.s003.tif
Supplemental Material - journal.pbio.3000651.s004.tif
Supplemental Material - journal.pbio.3000651.s005.xlsx
Supplemental Material - journal.pbio.3000651.s006.xlsx
Supplemental Material - journal.pbio.3000651.s007.xlsx
Supplemental Material - journal.pbio.3000651.s008.xlsx
Supplemental Material - journal.pbio.3000651.s009.xlsx
Supplemental Material - journal.pbio.3000651.s010.xlsx
Supplemental Material - journal.pbio.3000651.s011.xlsx
Supplemental Material - journal.pbio.3000651.s012.xlsx
Supplemental Material - journal.pbio.3000651.s013.xlsx
Supplemental Material - journal.pbio.3000651.s014.xlsx
Supplemental Material - journal.pbio.3000651.s015.xlsx
Supplemental Material - journal.pbio.3000651.s016.xlsx
Supplemental Material - journal.pbio.3000651.s017.pdf
Supplemental Material - journal.pbio.3000651.s018.xlsx
Supplemental Material - journal.pbio.3000651.s019.xlsx
Supplemental Material - journal.pbio.3000651.s020.xlsx
Supplemental Material - journal.pbio.3000651.s021.xlsx
Files
Name | Size | Download all |
---|---|---|
md5:26b7c3b3bf563406d3e7abbae1054129
|
9.5 MB | Preview Download |
md5:9a2b08d8d9aa21e546d5485826bcc92c
|
2.4 MB | Preview Download |
md5:8d9ab80e1862da6861de73558e254c9e
|
121.3 kB | Download |
md5:51aa60f542abd015ce0b2fa339f33d17
|
4.8 MB | Preview Download |
md5:c1a5ad267b371901167b392bda36dded
|
10.1 MB | Preview Download |
md5:94d25234b685afd8e8e6e619e615c4b2
|
6.7 MB | Preview Download |
md5:cb30484d3223a35a6b24e64da9602973
|
27.1 kB | Download |
md5:53071bd4f59fc6dde5defcf239f37ed8
|
18.1 kB | Download |
md5:22c8b6da7dc0b96de6916be9d6f7eedc
|
18.2 kB | Download |
md5:7be1038cc001de1aa288a5383893e1c0
|
20.0 kB | Download |
md5:a549e5ed272586de2614895846153aa3
|
16.7 kB | Download |
md5:b91fcb339f1f63e25998870ba2e71540
|
31.6 kB | Download |
md5:8c4d3d9603accc40249a6eefb816c317
|
122.0 kB | Download |
md5:c237bdfc4aa2a01186ebe5ac5763df39
|
120.9 kB | Download |
md5:f6b59fd6a9318e879d7f9d39485067aa
|
121.3 kB | Download |
md5:a16a814dbf1fa6ee191e88379b0ddb23
|
18.6 kB | Download |
md5:3085c37de9791a2abee373ae083e3bc1
|
15.4 kB | Download |
md5:52073f492f7b109523dcce0e16dad52d
|
15.9 kB | Download |
md5:4ff067a7314335a77e1937930bab0ade
|
19.1 kB | Download |
md5:d77262eff43a4eb23e806237e2582b97
|
23.2 kB | Download |
md5:08fdb587c781397b20dd045f70ed004c
|
20.5 kB | Download |
md5:4d4e5fb7f90d603a7ae06270229d309c
|
13.0 kB | Preview Download |
Additional details
- PMCID
- PMC7081974
- Eprint ID
- 102004
- Resolver ID
- CaltechAUTHORS:20200319-141031875
- Department of Health and Human Services
- Wellcome Trust
- IDSEP160030-02
- Burroughs Wellcome Fund
- 1014981
- NIH Predoctoral Fellowship
- 5T32GM07616NSF
- Joseph J. Jacobs Institute for Molecular Engineering for Medicine
- Joan and Jerry Doren
- Created
-
2020-03-19Created from EPrint's datestamp field
- Updated
-
2023-06-01Created from EPrint's last_modified field
- Caltech groups
- Jacobs Institute for Molecular Engineering for Medicine, Division of Biology and Biological Engineering (BBE)